Mylan, Apotex Secure FDA Approval For Generic Boniva

Law360, New York (March 19, 2012, 8:19 PM EDT) -- The U.S. Food and Drug Administration on Monday approved the first generic versions of the popular osteoporosis drug Boniva, opening the door to generic-drug makers Mylan Pharmaceuticals Inc., Apotex Inc. and Orchid Healthcare to compete with F. Hoffman-La Roche Ltd.'s blockbuster treatment. 

Boniva, manufactured and distributed by Roche subsidiary Genentech Inc., boosts bone mass to curb the onset of the chronic disease in post-menopausal women and to help reduce the likelihood of its effects on the body, like spinal fractures, the FDA said in its statement.

The market...
To view the full article, register now.